Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Last trade$6.60
Day change-$0.17 (-2.51%)
Day range$6.46 – $7.90
Volume796,392
Market cap$443M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$443.33M
Price / earnings
—
Price / book
0.86×
Price / sales
1.61×
EV / sales
1.29×
EV / EBITDA
-15.53×
Profitability
Earnings per share
-$0.15
Return on assets
-1.56%
Return on equity
-1.85%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.39×
Quick ratio
8.39×
Cash ratio
1.26×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$159.8M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARVN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$500K
$249.7M
$15.6M
$9.5M
$41.9M
$22.4M
$188.8M
$59.2M
Cost of revenue
$100K
$9M
$0
$0
$0
$0
$0
$0
Gross profit
$400K
$240.7M
$15.6M
$9.5M
$41.9M
$22.4M
$188.8M
$59.2M
Selling, general and administrative
$12.6M
$24M
$19.1M
$23M
$21M
$25.3M
$26.6M
$34.1M
Research and development
$46.9M
$52.6M
$60.3M
$61.1M
$64.7M
$68.6M
$90.8M
$83.3M
Total operating expenses
$59.5M
$76.6M
$79.4M
$84.1M
$85.7M
$93.9M
$117.4M
$117.4M
Operating income
-$59.1M
$164.1M
-$63.8M
-$74.6M
-$43.8M
-$71.5M
$71.4M
-$58.2M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$53.7M
$169.6M
-$57.5M
-$67.2M
-$34.8M
-$61.5M
$83.1M
-$45.5M
Income taxes
$200K
$200K
$100K
$200K
$300K
-$300K
$200K
-$400K
Net income
-$53.9M
$169.4M
-$57.6M
-$67.4M
-$35.1M
-$61.2M
$82.9M
-$45.1M
Net income attributable to common shareholders
-$53.9M
$169.4M
-$57.6M
-$67.4M
-$35.1M
-$61.2M
$82.9M
-$45.1M
EBITDA
-$55M
$164.5M
-$62.8M
-$69.6M
-$38.9M
-$74M
$75.4M
-$52.5M
Basic earnings per share
-$0.82
$2.61
-$0.90
-$1.04
-$0.48
-$0.84
$1.14
-$0.63
Diluted earnings per share
-$0.82
$2.58
-$0.90
-$1.04
-$0.48
-$0.84
$1.14
-$0.63
Recent news
Company coverage with links to the original publishers.
Arvinas, a clinical-stage biotech company specializing in protein degradation therapies, announced management participation in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company will present preliminary clinical data from early monotherapy dose escalation cohorts of ARV-393 (Zaloblideg), a PROTAC BCL6 degrader, at the 2026 American Society of Hematology Annual Meeting, including safety, pharmacokinetics, and pharmacodynamics data.
Arvinas (ARVN) reported a quarterly loss of $0.82 per share, slightly missing the consensus estimate of $0.80, with revenues of only $0.5 million versus expectations of $25.51 million. The company's stock has declined 36.6% year-to-date, significantly underperforming the S&P 500's 10.2% gain. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026. Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space.
Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.
Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.